Antihypertensive drugs and reversing of endothelial dysfunction in hypertension
Antihypertensive drugs and reversing of endothelial dysfunction in hypertension
复制标题
抗高血压药物和逆转高血压内皮功能障碍
DOI:
10.1007/s11906-000-0061-8
复制
发表时间:
2000
影响因子:
5.6
通讯作者:
A. Salvetti
中科院分区:
文献类型:
--
作者:
S. Taddei;A. Virdis;L. Ghiadoni;I. Sudano;A. Salvetti
Essential hypertension is associated with impaired endothelium-dependent vasodilation and is caused mainly by production of oxygen free radicals that can destroy nitric oxide (NO), impairing its beneficial and protective effects on the vessel wall. Antihypertensive drugs can improve or restore endothelium-dependent vasodilation depending on their ability to counteract the mechanisms that impair endothelial function. Although treatment with atenolol gives negative results in peripheral subcutaneous and muscle microcirculation, acute nebivolol exerts a modest vasodilating effect in the forearm circulation. Whether this compound can activate NO production in essential hypertensive patients is controversial. Calcium entry blockers, particularly the dihydropyridine-like drugs, can reverse impaired endothelium-dependent vasodilation in different vascular districts, including the subcutaneous, epicardial, and peripheral arteries and forearm circulation. In the forearm circulation, nifedipine and lacidipine can improve endothelial dysfunction by restoring NO availability. Angiotensin-converting enzyme (ACE) inhibitors, however, seem to improve endothelial function in subcutaneous, epicardial, and renal circulation, but are ineffective in potentiating the blunted response to acetylcholine in the forearm of patients with essential hypertension. Finally, recent evidence suggests angiotensin II receptor antagonists can restore endothelium-dependent vasodilation t acetylcholine in subcutaneous, but not in the forearm muscle, microcirculation. However, treatment with an angiotensin II receptor antagonist can improve basal NO release and decrease the vasoconstrictor effect of endogenous endothelin-1.
登录
查看更多内容
影响因子:
15.9
作者:
Rajagopalan, S;Kurz, S;Harrison, DG
通讯作者:
Harrison, DG
影响因子:
20.1
作者:
GRIENDLING, KK;MINIERI, CA;ALEXANDER, RW
通讯作者:
ALEXANDER, RW
DOI:
10.1161/01.hyp.26.1.164
发表时间:
1995
期刊:
Hypertension (Dallas, Tex. : 1979)
影响因子:
--
作者:
Seyedi,N;Xu,X;Nasjletti,A;Hintze,TH
通讯作者:
Hintze,TH
影响因子:
3
作者:
Vanhoutte,PM
通讯作者:
Vanhoutte,PM
影响因子:
--
作者:
KATUSIC, ZS;VANHOUTTE, PM
通讯作者:
VANHOUTTE, PM